These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

326 related articles for article (PubMed ID: 38022905)

  • 1. Current investigations for liver fibrosis treatment: between repurposing the FDA-approved drugs and the other emerging approaches.
    Mohammed OS; Attia HG; Mohamed BMSA; Elbaset MA; Fayed HM
    J Pharm Pharm Sci; 2023; 26():11808. PubMed ID: 38022905
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatic fibrosis: molecular mechanisms and drug targets.
    Lotersztajn S; Julien B; Teixeira-Clerc F; Grenard P; Mallat A
    Annu Rev Pharmacol Toxicol; 2005; 45():605-28. PubMed ID: 15471534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Are we any closer to treating liver fibrosis (and if no, why not)?
    Feng R; Yuan X; Shao C; Ding H; Liebe R; Weng HL
    J Dig Dis; 2018 Mar; 19(3):118-126. PubMed ID: 29389083
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in anti hepatic fibrotic therapy with Traditional Chinese Medicine herbal formula.
    Li H
    J Ethnopharmacol; 2020 Apr; 251():112442. PubMed ID: 31891799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Repurposing drugs to target nonalcoholic steatohepatitis.
    Sookoian S; Pirola CJ
    World J Gastroenterol; 2019 Apr; 25(15):1783-1796. PubMed ID: 31057294
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sorafenib: A potential therapeutic drug for hepatic fibrosis and its outcomes.
    Ma R; Chen J; Liang Y; Lin S; Zhu L; Liang X; Cai X
    Biomed Pharmacother; 2017 Apr; 88():459-468. PubMed ID: 28122312
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pathophysiology and a Rational Basis of Therapy.
    Gracia-Sancho J; Maeso-Díaz R; Bosch J
    Dig Dis; 2015; 33(4):508-14. PubMed ID: 26159267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A critical review on anti-fibrotic phytochemicals targeting activated hepatic stellate cells.
    Vijayan N; Perumal MK
    J Food Biochem; 2022 Dec; 46(12):e14438. PubMed ID: 36209494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hepatic Antifibrotic Pharmacotherapy: Are We Approaching Success?
    Chang Y; Li H
    J Clin Transl Hepatol; 2020 Jun; 8(2):222-229. PubMed ID: 32832403
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liver fibrosis and hepatic stellate cells: Etiology, pathological hallmarks and therapeutic targets.
    Zhang CY; Yuan WG; He P; Lei JH; Wang CX
    World J Gastroenterol; 2016 Dec; 22(48):10512-10522. PubMed ID: 28082803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: emerging anti-fibrotic therapies in the treatment of non-alcoholic steatohepatitis.
    Noureddin M; Anstee QM; Loomba R
    Aliment Pharmacol Ther; 2016 Jun; 43(11):1109-23. PubMed ID: 27061197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reversal of NASH fibrosis with pharmacotherapy.
    Alukal JJ; Thuluvath PJ
    Hepatol Int; 2019 Sep; 13(5):534-545. PubMed ID: 31363910
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Collagenase-I decorated co-delivery micelles potentiate extracellular matrix degradation and hepatic stellate cell targeting for liver fibrosis therapy.
    Zhou L; Liang Q; Li Y; Cao Y; Li J; Yang J; Liu J; Bi J; Liu Y
    Acta Biomater; 2022 Oct; 152():235-254. PubMed ID: 36087869
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Liver Fibrosis Resolution: From Molecular Mechanisms to Therapeutic Opportunities.
    Pei Q; Yi Q; Tang L
    Int J Mol Sci; 2023 Jun; 24(11):. PubMed ID: 37298621
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New Developments on the Treatment of Liver Fibrosis.
    Koyama Y; Xu J; Liu X; Brenner DA
    Dig Dis; 2016; 34(5):589-96. PubMed ID: 27332862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evolving Role for Pharmacotherapy in NAFLD/NASH.
    Attia SL; Softic S; Mouzaki M
    Clin Transl Sci; 2021 Jan; 14(1):11-19. PubMed ID: 32583961
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapies for hepatic fibrosis.
    Koyama Y; Brenner DA
    Clin Res Hepatol Gastroenterol; 2015 Sep; 39 Suppl 1(0 1):S75-9. PubMed ID: 26206573
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The pharmacological approach to reverse portal hypertention and hepatic schistosomal fibrosis in Egypt, control experimental study.
    Helmy AH; Abdel-Hady AA; el-Shanawany F; Hammam O; Abdel-Hady A
    J Egypt Soc Parasitol; 2005 Dec; 35(3):731-50. PubMed ID: 16333884
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel targeted therapies for the management of liver fibrosis.
    Trivella JP; Martin P; Carrion AF
    Expert Opin Emerg Drugs; 2020 Mar; 25(1):59-70. PubMed ID: 32098512
    [No Abstract]   [Full Text] [Related]  

  • 20. Safety and therapeutic effects of anti-fibrotic Traditional Chinese Medicine Fuzheng Huayu on persistent advanced stage fibrosis following 2 years entecavir treatment: Study protocol for a single arm clinical objective performance criteria trial.
    Chen Y; Zhao Z; Fan H; Li Z; He Y; Liu C
    Contemp Clin Trials Commun; 2020 Sep; 19():100601. PubMed ID: 32642592
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.